All In Biotech

Drug Trial Radar · NCT00819234

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin in Obese and Overweight Subjects

Last checked: Nov 20, 2026Latest source record: Apr 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 274 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

274

Actual

Start

Nov 2008

Primary completion

Oct 2009

Study completion Nov 2009

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 8, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study DFA102E is an extension of Study DFA102, which included a 28-week treatment period with randomized study medication. The purpose of the extension study is to examine the long-term (up to 1 year) safety, tolerability, and effect on body weight of treatment with pramlintide and metreleptin, administered as separate subcutaneous (SC) injections, in obese and overweight subjects.

Conditions

  • Obesity

Interventions

  • PlaceboDrug

    placebo pramlintide and placebo metreleptin twice daily

  • Pramlintide and MetreleptinDrug

    Subcutaneous injection, twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. LS Mean Percent Change in Body Weight From Original Study DFA102 (NCT00673387) Baseline (Day 1) at Week 52 in Extension Study DFA102E - Evaluable Treatment Stable PopulationTime frame: Original Study Baseline to Week 52

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Phoenix, Arkansas

  • Research Site

    Santa Rosa, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Denver, Colorado

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Plantation, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Springfield, Illinois

  • Research Site

    Kansas City, Kansas

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Boston, Massachusetts

  • Research Site

    Edina, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Butte, Montana

  • Research Site

    New York, New York

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Eugene, Oregon

  • Research Site

    Medford, Oregon

  • Research Site

    Anderson, South Carolina

  • Research Site

    Greer, South Carolina

  • Research Site

    Mt. Pleasant, South Carolina

  • Research Site

    Nashville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Norfolk, Virginia

  • Research Site

    Bellingham, Washington

  • Research Site

    Olympia, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.